The Use of Treosulfan and Gemcitabine in the Treatment of Platinum-Resistant Ovarian Cancer

Oncology Letters - Greece
doi 10.3892/ol_00000038
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Targeted Treatment of Recurrent Platinum-Resistant Ovarian Cancer: Current and Emerging Therapies

Cancer Management and Research
Oncology
2010English

Oral Melphalan as a Treatment for Platinum-Resistant Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2003English

Is HIPEC Beneficial in Platinum Resistant Relapsed Ovarian Cancer?

Romanian Journal of Medical Practice
2019English

Prm212 - Patient Experience With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

A Phase II Study of the Combination Chemotherapy of Bevacizumab and Gemcitabine in Women With Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Journal of Ovarian Research
GynecologyOncologyObstetrics
2020English

Establishment and Characterization of the Gemcitabine‑resistant Human Pancreatic Cancer Cell Line SW1990/gemcitabine

Oncology Letters
Cancer ResearchOncology
2019English

Bevacizumab in the Treatment of Ovarian Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2011English

The Use of Monoclonal Antibodies for the Treatment of Epithelial Ovarian Cancer (Review)

International Journal of Oncology
Cancer ResearchOncology
2008English

Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab

Clinical Medicine Insights: Oncology
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy